TCC Case Study: Sir Oliver
Sir Oliver, an 8 year old French Bulldog with TCC, is surviving and thriving thanks to his targeted therapeutic treatment4.5 months from FidoCure™ enrollment, Sir Oliver's latest CT scan showed a 38% reduction in his bladder tumor.
Sir Oliver, an 8 year old French Bulldog with TCC, is surviving and thriving thanks to his targeted therapeutic treatment
4.5 months from FidoCure™ enrollment, Sir Oliver's latest CT scan showed a 38% reduction in his bladder tumor.
We are excited to share with you another one of our FidoCure™ canine cancer warriors.
Sir Oliver Heymers, an 8-year old French Bulldog, is surviving and thriving, thanks to his targeted therapeutic, trametinib, a MAP2K1 and MAP2K2 inhibitor. His latest CT scan showed a reduction in his bladder tumor by 38%, 4.5 months following FidoCure™ enrollment.
Sir Oliver presented to his veterinarian in November, 2018, with hematuria. Tumor cells were found in his urinalysis sample and he was diagnosed with transitional cell carcinoma (TCC). TCC is a malignant tumor of the urinary bladder that often arises from the trigone of the bladder, making surgical removal extremely difficult. Only approximately 30% of TCCs respond to traditional chemotherapy, so we are thrilled to have this result with a targeted therapy.
When Sir Oliver was diagnosed with TCC, his family and veterinarian elected to enroll in FidoCure™ and treat him with targeted therapy. Sir Oliver’s response has been phenomenal and his family reports he is “acting years younger” and they are “finally really seeing a difference in him”. In addition, the hematuria has almost completely resolved.
Nothing makes us happier than to see a targeted therapy option create a significant impact on quantity and quality of life for patients. The data we collected in Sir Oliver’s case will help future dogs, and ultimately, humans, receive better, more personalized, cancer care.